(Premium) – Fidelity National Information Services (FIS) and Worldpay are closer to get all the necesary approvals for their $34 billion deal after the FTC cleared the operation in April 26. This mega merger isn’t likely to raise antitrust concerns and it may trigger more FinTech/payment M&A in 2019.
Continue Reading
(Premium) – Thyssenkrupp and Tata will likely need to beef up their remedy package to win EU antitrust approval by June 17. Yet, additional divestitures may affect the rationale of the deal.
Continue Reading
(Premium) – Bristol-Myers Squibb’s proposed $74 billion acquisition of Celgene is likely to get a phase one approval in Europe, though requirements of small divestitures can’t be ruled out. The companies’ overlap in broad segments won’t raise antitrust concerns.
Continue Reading
(Premium) – The Siemens-Alstom deal is about to collapse unless the companies are willing to divest additional high-speed trains. The initial remedy package seems insufficient to appease EU regulators. For Siemens the cost of divesting additional high-speed trains may render the deal unattractive.
Continue Reading
(Premium) – AT&T appears likely to prevail in the Justice Department’s appeal of a trial court’s ruling clearing the AT&T-Time Warner deal. A decision is likely in 1Q18
Continue Reading
(Premium) – CME and NEX shouldn’t find any opposition from the U.K. Competition and Markets Authority (CMA) to clear their $5.4 billion deal. Minimal horizontal overlaps and the parties’ complementary businesses suggest the merger review should end with a phase-one approval by year-end.
Continue Reading
(Premium) – The companies are likely to be cleared after a second-phase merger review but they may need to divest general-purpose hardware security modules (GP HSM) to secure a DG Comp’s nod.
Continue Reading